News about "Innovent Biologics"

Innovent Doses First Patient in Phase III Trial of Tigulixostat for Gout

Innovent initiates Phase III study of tigulixostat against febuxostat in Chinese gout patients, aiming to deliver improved uric acid control and better safety outcomes.

Innovent Biologics | 23/03/2026 | By News Bureau

Innovent Doses First Patient in Phase III Trial of IBI354 for First-Line HER2-Positive Advanced Breast Cancer

HeriCare-Breast01 study evaluates next-generation HER2 ADC against standard THInnovent BiologicsP regimen, following promising phase I/II efficacy and safety data presented at ASCO 2025.

Innovent Biologics | 16/02/2026 | By News Bureau |  157

Innovent Biologics and Eli Lilly Forge Strategic Collaboration in Oncology and Immunology

Innovent Biologics will receive USD 350 million upfront and up to USD 8.5 billion in milestones under a new global development pact, with Lilly securing ex-Greater China rights to novel oncology and immunology programmes.

Innovent Biologics | 10/02/2026 | By News Bureau |  118

Innovent Collaborates with Lilly to Develop New Medicines in Oncology and Immunology

The agreement grants Lilly an exclusive licence to develop and commercialise the programmes worldwide outside Greater China, while Innovent retains rights in Greater China.

Innovent Biologics | 09/02/2026 | By News Bureau

Innovent's Tri-Specific Antibody IBI3003 Secures FDA Fast Track Status for Relapsed/Refractory Multiple Myeloma

Innovent Biologics’ tri-specific antibody IBI3003 has received FDA Fast Track Designation for heavily pretreated relapsed or refractory multiple myeloma, supported by promising early clinical efficacy and safety data.

Innovent Biologics | 27/01/2026 | By News Bureau |  205

Innovent TABOSUN Becomes China's First Approved Domestic Anti CTLA 4 Antibody

Innovent Biologics has received approval from China’s National Medical Products Administration (NMPA) for TABOSUN (Ipilimumab N01 Injection), marking the country’s first domestically developed anti-CTLA-4 monoclonal antibody and a significant milestone in China’s immuno-oncology landscape.

Innovent Biologics | 26/12/2025 | By News Bureau |  329

Innovent Biologics and Takeda Finalise Global Collaboration for Next-Generation IO and ADC Therapies

As part of the agreement, Takeda will pay Innovent an upfront payment of USD1.2 billion, including a USD100 million equity investment at HKD112.56 per share.

Innovent Biologics | 05/12/2025 | By Dineshwori |  133

Innovent's PECONDLE Becomes China's First Approved IL-23p19 Antibody

Innovent has received NMPA approval for PECONDLE (picankibart injection), marking China’s first IL-23p19 monoclonal antibody to be cleared for treating moderate-to-severe plaque psoriasis in adults eligible for systemic therapy.

Innovent Biologics | 02/12/2025 | By Dineshwori |  268

Innovent Gets Second Fast Track Designation from FDA for IBI363

This designation applies to the treatment of unresectable, locally advanced, or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed following anti-PD-(L)1 immune checkpoint inhibitor therapy and platinum-based chemotherapy.

Innovent Biologics | 17/02/2025 | By Aishwarya |  334

Innovent's DOVBLERON Secures Second NMPA Approval for ROS1-Positive NSCLC

China's National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON®, a next-generation ROS1 tyrosine kinase inhibitor (TKI).

Innovent Biologics | 03/01/2025 | By Abha |  311